Join Dr. JD Corl, Interventional Cardiologist and Medical Director of the PAD/CLI Program at The Linder Center for Research and Education at the Christ Hospital, as he provides an overview of the first-of-its-kind Forward Intravascular Lithotripsy (IVL) Platform, Shockwave Javelin, and reviews three patient cases from the Forward PAD Investigational Device Exemption (IDE) Trial.

In this Shockwave Javelin case review, Dr. Vasili Lendel, Interventional Cardiologist at Arkansas Heart Hospital, Little Rock, AR, reviews a clinical case involving a patient with severe tibial peroneal (TP) trunk stenosis and anterior and posterior tibial occlusions, before diving into a Q&A discussion about Shockwave Javelin.

Case Summary

Patient background:

• 79-year-old male with a history of paroxysmal atrial fibrillation (PAF), hypertension, chronic kidney disease and type II diabetes
• Resting pain; symptoms remained refractory despite maximal medical and physical therapy
• Computed tomographic angiography (CTA) showed occluded anterior tibial (AT) artery, severe stenosis of the TP trunk with occluded posterior tibial artery (PT)
  • Renovascular disease (RVD): 2.5 – 3 mm
  • Lesion length: 120 mm

Treatment algorithm:

• 6 Fr 90 cm sheath
• 0.014″ guidewire was advanced into the distal PT
• Unable to advance 0.014 support catheter
• Shockwave Javelin was chosen to help cross and modify the calcified lesion

Treatment:

• Unable to cross the distal cap using Gaia next 3 and Astato XS 20 wires
• Shockwave Javelin was replaced for 0.018″ Crosswalk
• Retrograde access was obtained via distal PT artery using ultrasound
• Antegrade catheter was cannulated using retrograde Sion black wire
• Shockwave Javelin brought to distal cap and treated with the remaining pulses
• Subsequently, the artery was treated using 2.5 x 80 mm Shockwave E8, followed by 3 x 200 Armada balloon

Result:

• Brisk flow in the posterior tibial and medial plantar arteries without flow-limiting dissection

Dr. Lendel is a paid consultant of Shockwave Medical. The thoughts and views expressed are of their own opinions and do not necessarily represent Shockwave Medical.

Shockwave IVL: In the U.S.: Rx only. Prior to use, please reference the Important Safety Information for more information on indications, contraindications, warnings, precautions and adverse events.

In this video series, Dr. Karthikeshwar Kasirajan, MD, Clinical Professor of Surgery at Stanford Health Care, CA, reviews two patient cases using Shockwave Javelin, our Forward Intravascular Lithotripsy (IVL) Platform.

Case 1: Recurrent Superficial Femoral Artery (SFA) Stenosis

• Female patient
• Lesion crossing 0.014″ guidewire with Shockwave Javelin
• 30% luminal gain post-Shockwave Javelin
• Followed by Shockwave E8 5.0 mm, drug-coated balloon (DCB) and stent

Case 2: Multilevel Disease: SFA, Popliteal & Distal Posterior Tibial

• 46-year-old male with end-stage renal disease (ESRD) and gangrene of the heel and first toe
• SFA & popliteal:
  • Lesion crossing with Shockwave Javelin
  • 30% luminal gain post-Shockwave Javelin
  • Followed by Shockwave E8 6.0 mm and DCB
• Distal PT occlusion:
  • PT and medial plantar crossing with Shockwave Javelin
  • 80% luminal gain post-Shockwave Javelin
  • Followed by percutaneous transluminal angioplasty (PTA) balloon

Dr. Kasirajan is a paid consultant of Shockwave Medical. The thoughts and views expressed are of their own opinions, and do not necessarily represent those of Shockwave Medical.

Shockwave IVL: In the U.S.: Rx only. Prior to use, please reference the Important Safety Information for more information on indications, contraindications, warnings, precautions and adverse events.

Unique Randomized Controlled Trial (RCT) Design Relevant for Clinical Practice

The BALI study is the first randomized study that examines the potential advantages of a routine Intravascular Lithotripsy (IVL) strategy versus conventional lesion preparation strategies in a rigorous, intracoronary imaging-guided, all-comers population with severely calcified lesions representative of real-world clinical practice.

• Recognizing that many calcium tools are complementary and atherectomy is a critical tool to be able to cross lesions, BALI compared 99 patients treated with IVL, 101 patients undergoing conventional balloon-based lesion preparation strategies, including cutting, scoring, ultra-high pressure balloons, and non-compliant (NC) balloons, but not IVL, across nine sites in Denmark, Norway, Estonia and Belgium.
• Rotational atherectomy was utilized in 31% of patients in the IVL arm and 42% of patients in the conventional lesion preparation arm only to facilitate balloon crossing.

Watch the BALI Trial Summary to learn why this study is important and for details on the study design and results.

Routine use of IVL Strategy Found Superior to Conventional Approaches

• 2/3 of patients with routine IVL were free of the primary endpoint, compared with approximately 1/2 of patients with conventional treatment arm, leading the BALI investigators to determine that at one year, a routine IVL strategy was the superior calcium modification strategy.
  • The primary endpoint of procedural failure (stent implantation with a residual area stenosis of ≥20%) or target vessel failure (CD, TVMI CD-TLR) at one year occurred in 35% of IVL patients and in 52% of conventional preparation patients (p_superiority = 0.02). 

Watch Dr. Niels Thue Olsen, MD, PhD, Clinical Associate Professor at the University of Copenhagen, and Chief Medical Officer at Shockwave Medical, Nick West, discuss more about the BALI study.

Key Takeaway

In patients undergoing percutaneous coronary intervention (PCI) for severely calcified coronary lesions, the use of lithotripsy before stent implantation reduced the incidence of procedural failure or target vessel failure at one year, without an increased risk of adverse events.

Dr. Niels Thue Olsen is a paid consultant of Shockwave Medical.

Views expressed are those of the authors and not necessarily those of Shockwave Medical.

Dr. Leah Raj (Interventional Cardiologist, Vanderbilt University Medical Center, TN) shares her thoughts on Intravascular Lithotripsy (IVL)’s mechanism of action (MOA) and how it modifies coronary calcium in under three minutes.

The ROLLING-STONE Registry is the largest, prospective, multi-center registry with a head-to-head comparison after propensity score matching (PSM) of Shockwave Intravascular Lithotripsy (IVL) versus rotational atherectomy (AT) in a real-world, all-comers population. The 1,005 patient registry compared the procedural success, intraprocedural complications and 30 day and 1 year MACE rates after PSM of IVL versus rotational atherectomy (RA) and orbital atherectomy (OA).

In this interview, we sat down with the lead investigator of the registry, Dr. Enrico Cerrato, San Luigi Gonzaga University Hospital and Rivoli Hospital, Italy, to discuss the outcomes of the ROLLING-STONE Registry and how he anticipates the results may impact the daily practice of interventional cardiologists.

Download the summary and watch our interview with Dr. Enrico Cerrato to learn more about the trial and to hear his perspective.

• Trial design: Prospective, multi-center, double-arm, all-comers study of 1,005 patients with moderate-severe calcification treated with atherectomy or IVL from 23 Italian institutions
• Safety endpoints: Freedom from MACE at 30 days and one year after PSM and inverse probability weighting (IPW) (core-lab adjudicated)
• Primary efficacy endpoint: Procedural success: stent delivery with residual stenosis <30% and absence of in-hospital MACE (core-lab adjudicated)

IVL demonstrates a favorable 30-day MACE and statistically significant lower 1-year MACE after PSM as compared to atherectomy

IVL demonstrates similar procedural success with favorable intraprocedural complications as compared to atherectomy

Download the summary

Cerrato, E. (2025, March). Intravascular Lithotripsy And/Or Mechanical Debulking Multicenter Registry For The Treatment Of Complex Calcified Coronary Arteries: Rolling Stone Registry. Cardiovascular Research Technologies (CRT) 2025.

Dr. Leigh Ann O’Banion (Associate Clinical Professor of Surgery Vascular Surgeon UCSF Fresno, CA) shares her thoughts on peripheral Intravascular Lithotripsy (IVL) sizing for optimal patient outcomes in under two minutes.

Dr. Leigh Ann O’Banion (Associate Clinical Professor of Surgery Vascular Surgeon UCSF Fresno, CA) shares her perspective on best practices to optimize peripheral Intravascular Lithotripsy (IVL) patient outcomes in under 3 minutes.

Rhian E. Davies, DO MS FACC FSCAI (Director of Complex Coronary Interventional Cardiology, WellSpan Health – York), shares her coronary Intravascular Lithotripsy (IVL) crossing techniques in under two minutes.

In this video series, Drs. Suzanne Baron, Kevin Croce and Nieves Gonzalo share their experiences with the Shockwave C2+ coronary Intravascular Lithotripsy (IVL) catheter in treating female patients with calcified coronary artery disease (CAD).

EMPOWER CAD is a prospective, multi-center, single-arm, female-only, all-comers study to generate real-world clinical evidence associated with coronary IVL.

Complex PCI in Women

Dr. Suzanne Baron outlines the growing need to EMPOWER, highlighting the studies that detail the discrepancies in percutaneous coronary interventions (PCI) between females and males.

Consistency Across the Sexes: IVL is Safe & Effective in Modifying Nodular Calcium in Men & Women¹

Case courtesy of Dr. Kevin Croce, Brigham and Women’s Hospital

Nodular calcium poses a big clinical problem that is predominantly represented in female patients. Calcified nodules have worse long-term outcomes than any other presentation of calcium. Shockwave IVL’s unique mechanism of action has proven to have a safer, more effective outcome when modifying nodular calcium compared to other atherectomy devices.²

Dr. Kevin Croce’s patient presented with a challenging tortuous nodular calcified lesion in the right coronary artery. After being unsuccessful in passing equipment through the lesion, a 1.5 Rota burr passed through the lesion. A post-atherectomy IVUS showed that rotational atherectomy supplied minimal benefit in modifying the calcium. A Shockwave IVL catheter was used and proved on IVUS to have a significant impact on the nodular calcium. Once the right coronary artery was fixed the left circumflex artery showed signs of nodular calcium on OCT. A Shockwave C2+ IVL catheter was used to successfully treat the nodular calcium safely and effectively. IVL has shown consistent MSA and stent expansion despite the presence of nodular calcium.

Consistent Results Regardless of Complex Anatomy

Case courtesy of Dr. Nieves Gonzalo, Clinico San Carlos University Hospital in Madrid

The main challenges for calcific lesion treatment in women are related with vessel size and tortuosity.³ Dr. Nieves Gonzalo’s patient presented with both challenges in the left anterior descending artery and the circumflex artery. After visualizing how severe the calcium was in both arteries, a 2.5 Shockwave C2+ catheter was used to modify the calcium. IVL has proven to be impactful and safe for the treatment of calcific coronary disease in females.

The physicians featured are paid consultants for Shockwave Medical.

1: Hill, J, Kereiakes, D, Shlofmitz, R. et al. Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease. JACC. 2020 Dec, 76 (22) 2635-2646. https://doi.org/10.1016/j.jacc.2020.09.603.
2: Ali ZA, Shin D, Singh M, Malik S, Sakai K, Honton B, Kereiakes DJ, Hill JM, Saito S, Mario CD, Gonzalo N, Riley RF, Maehara A, Matsumura M, Hokama J, West NEJ, Stone GW, Shlofmitz RA. Outcomes of coronary intravascular lithotripsy for the treatment of calcified nodules: a pooled analysis of the Disrupt CAD studies. EuroIntervention. 2024 Dec 2;20(23):e1454-e1464. doi: 10.4244/EIJ-D-24-00282. PMID: 39618263; PMCID: PMC11586657.
3: Equity in Modifying Plaque of Women With Undertreated Calcified Coronary Artery Disease: Design and Rationale of EMPOWER CAD study McEntegart, Margaret et al. Journal of the Society for Cardiovascular Angiography & Interventions, Volume 3, Issue 11, 102289.

Shockwave IVL: In the U.S.: Rx only. Prior to use, please reference the Important Safety Information for more information on indications, contraindications, warnings, precautions and adverse events.